Pharmacologically reversible zonation-dependent endothelial cell transcriptomic changes with neurodegenerative disease associations in the aged brain.
Nat Commun · 2020
Last updated 2026-05-28A study in aged mice found that brain blood vessel cells show changes in gene activity linked to immune signaling and energy use, particularly in small vessels. These changes resemble patterns seen in human Alzheimer’s brains. Giving the GLP-1 drug exenatide reversed many of these changes and reduced blood-brain barrier leakage in the mice.
AI summary of the abstract below.
| Journal | Nat Commun, 2020 |
|---|---|
| Citations | 96 |
| Relative citation ratio | 4.47 |
| NIH percentile | 91 |
| Molecules | — |
| Conditions studied | Alzheimers, Parkinsons |
Abstract
The molecular signatures of cells in the brain have been revealed in unprecedented detail, yet the ageing-associated genome-wide expression changes that may contribute to neurovascular dysfunction in neurodegenerative diseases remain elusive. Here, we report zonation-dependent transcriptomic changes in aged mouse brain endothelial cells (ECs), which prominently implicate altered immune/cytokine signaling in ECs of all vascular segments, and functional changes impacting the blood-brain barrier (BBB) and glucose/energy metabolism especially in capillary ECs (capECs). An overrepresentation of Alzheimer disease (AD) GWAS genes is evident among the human orthologs of the differentially expressed genes of aged capECs, while comparative analysis revealed a subset of concordantly downregulated, functionally important genes in human AD brains. Treatment with exenatide, a glucagon-like peptide-1 receptor agonist, strongly reverses aged mouse brain EC transcriptomic changes and BBB leakage, with associated attenuation of microglial priming. We thus revealed transcriptomic alterations underlying brain EC ageing that are complex yet pharmacologically reversible.
Verbatim abstract via PubMed 32887883 ↗